NTII: Neurobiological Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTII: Neurobiological Technologies

NTII 0.0001000

0.0%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Howard Frederick who wrote (28)	9/19/1997 8:24:00 AM
From: Dr. John M. de Castro	of 36

NTII told me that Dynborphin A was simply too expensive to manufacture for it to be an economically viable alternative to morphine. Why they proceeded into Phase II trials knowing this is a mystery to me. However, the fact that they are now being straight with it and emphasizing the truely valuable drugs, memantine and Xerecept,in the pipe is an excellent sign of management honesty and focus. The Orphan Drug application is also another sign that management is on top of things. This provides an advantage for NTII for the future. It is a little thing that prior leadership probably would have overlooked. I'm long and holding. I expect NTII to be in the $5-$8 range by years end. But it will really take off on Memantine results in early 98. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next